NO996182L - Krystallinsk roksifiban - Google Patents

Krystallinsk roksifiban

Info

Publication number
NO996182L
NO996182L NO996182A NO996182A NO996182L NO 996182 L NO996182 L NO 996182L NO 996182 A NO996182 A NO 996182A NO 996182 A NO996182 A NO 996182A NO 996182 L NO996182 L NO 996182L
Authority
NO
Norway
Prior art keywords
roxifiban
crystalline
polymorphic forms
crystalline roxifiban
treating
Prior art date
Application number
NO996182A
Other languages
English (en)
Other versions
NO996182D0 (no
Inventor
Michael B Maurin
Philip Ma
David J Meloni
Jaan A Pesti
Lucius Thomas Rossano
Randall K Ward
Jianguo Yin
Lin-Hua Zhang
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO996182L publication Critical patent/NO996182L/no
Publication of NO996182D0 publication Critical patent/NO996182D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den potente blodplateglykoprotein Ilb/IIIa-antagonisten, roksifiban, er fremstilt i krystallinsk form. Krystallinsk roksifiban eksisterer i to polymorfe former, angitt form l og form 2. Disse polymorfe formene er kjennetegnet ved rontgenpulverdiffraksjon og faststoffkarbon NMR. Farmasøytiske sammense:ninger og fremgangsmåter for behandling eller forebygging av sykdommer formidlet ved blodplateaggregering er beskrevet.
NO996182A 1997-06-16 1999-12-14 Krystallinsk roksifiban NO996182D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4963397P 1997-06-16 1997-06-16
US4971297P 1997-06-16 1997-06-16
US8027898P 1998-04-01 1998-04-01
PCT/US1998/012367 WO1998057939A1 (en) 1997-06-16 1998-06-12 Crystalline roxifiban

Publications (2)

Publication Number Publication Date
NO996182L true NO996182L (no) 1999-12-14
NO996182D0 NO996182D0 (no) 1999-12-14

Family

ID=27367578

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996182A NO996182D0 (no) 1997-06-16 1999-12-14 Krystallinsk roksifiban

Country Status (18)

Country Link
US (1) US6306886B1 (no)
EP (1) EP0991630A1 (no)
JP (1) JP2002504153A (no)
KR (1) KR20010013790A (no)
CN (1) CN1259940A (no)
AR (2) AR016070A1 (no)
AU (1) AU751198B2 (no)
CA (1) CA2294047A1 (no)
EA (1) EA200000028A1 (no)
EE (1) EE9900573A (no)
HR (1) HRP980291A2 (no)
HU (1) HUP0004755A3 (no)
IL (1) IL132618A0 (no)
NO (1) NO996182D0 (no)
NZ (1) NZ502077A (no)
PL (1) PL337612A1 (no)
SK (1) SK166699A3 (no)
WO (1) WO1998057939A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
RS54677B1 (sr) * 2010-05-27 2016-08-31 E. I. Du Pont De Nemours And Company Kristalni oblici 4-[5-[3-hloro-5-(trifluorometil)fenil]-4,5 -dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida
ES2600053T5 (es) * 2011-05-17 2023-04-28 Zetacube S R L Procedimiento de detección de polimorfos que utiliza una radiación de sincrotrón
GB2515783B (en) * 2013-07-03 2018-07-11 Rotam Agrochem Int Co Ltd Process for preparing clomazone, a form and use of the same
KR20240037628A (ko) 2022-09-15 2024-03-22 문혜경 그래핀이 함유된 고강도 내열 안경렌즈 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0730590T3 (da) * 1993-11-24 2001-03-19 Du Pont Pharm Co Isoxazolin og isozazol fibrinogenreceptorantagonister
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists

Also Published As

Publication number Publication date
AU751198B2 (en) 2002-08-08
KR20010013790A (ko) 2001-02-26
HUP0004755A2 (hu) 2001-07-30
CA2294047A1 (en) 1998-12-23
IL132618A0 (en) 2001-03-19
JP2002504153A (ja) 2002-02-05
AR023840A2 (es) 2002-09-04
CN1259940A (zh) 2000-07-12
AR016070A1 (es) 2001-06-20
PL337612A1 (en) 2000-08-28
US6306886B1 (en) 2001-10-23
NZ502077A (en) 2002-03-01
HUP0004755A3 (en) 2002-10-28
EE9900573A (et) 2000-08-15
SK166699A3 (en) 2001-09-11
AU8071998A (en) 1999-01-04
NO996182D0 (no) 1999-12-14
EA200000028A1 (ru) 2000-08-28
WO1998057939A1 (en) 1998-12-23
HRP980291A2 (en) 1999-04-30
EP0991630A1 (en) 2000-04-12

Similar Documents

Publication Publication Date Title
FI830100L (fi) Nya 6-substituerade s-triazolo /3,4-a/ ftalazinderivat
ZA883528B (en) Tetrazole intermediates to antihypertensive compounds
BG102616A (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives and their application
CA2014008A1 (en) Benzimidazoles, medicaments containing these compounds and processes for their preparation
DK164479C (da) Sucralfatsuspension og fremgangsmaade til fremstilling af denne
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
IN2012DE00109A (no)
DE69132141D1 (de) Neuroprotective indolone und verwandte derivate
MA20084A1 (fr) Derives de la furo-(3,4-c)-pyridine leur preparation et compositions therapeutiques contenant ces derives.
SE8004745L (sv) Nya tripeptider, som inverkar pa det centrala nervsystemet, jemte sett for deras framstellning
NO996182L (no) Krystallinsk roksifiban
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
IL61361A (en) N-aryl-n'-imidazol-2-ylureas,their preparation and pharmaceutical compositions containing them
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
GB1520162A (en) Bone joint prosthesis
PT84716A (en) Process for the preparation of insecticidal compositions containing six-membered heterocyclic derivatives of n:-substituted-n,n:-diacylhydrazines
BG34610A3 (en) Method for preparating 2', 6'- dialkyl- n- (alkoxymethyl)- 2- chloracetanylides
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
DE3060669D1 (en) Phenylalanyl-tryptophan derivatives, pharmaceutical compositions containing them, their preparation and use
ES8604731A1 (es) Un metodo de preparar derivados de 6,11-dihidrodibenz (b,e) oxepina
YU3701A (sh) Supstituisani fenilamidini sa antitrombskim dejstvom
ES531447A0 (es) Procedimiento de preparar derivados de n-cicloalcoilmetil-2 oxo-3 diaril 5-6 as triacina
IL113162A (en) Crystal forms of 1-[5-methanesulfon-amidoindolyl-2-carbonyl]-4[3(1-methylethylamino)-2-pyridinyl]piperazine
ZA908679B (en) (1r,2r)-2-(3-pyridyl)-tetrahydrothiopyran-2-carbothioamide 1-oxides,process for their preparation and pharmaceutical compositions containing them
JPS55127379A (en) Novel 33sulfonyllbenzoo1*2*44triazine and 33sulfonyllbenzoo1*2*44triazinee11oxide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application